Literature DB >> 18720517

Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration.

Junchao Tong1, Alan A Wilson, Isabelle Boileau, Sylvain Houle, Stephen J Kish.   

Abstract

Binding of (+)-[11C]DTBZ (dihydrotetrabenazine) to the striatal vesicular monoamine transporter (VMAT2) is widely considered to be a stable marker of dopamine neurone integrity. However, we now find that specific binding of a tracer dose of (+)-[11C]DTBZ is modestly increased in rat striatum following dopamine depletion with alpha-methyl-p-tyrosine (alpha-MPT, +14%) or d-amphetamine (d-AMPH, 20 mg/kg, +12%) and decreased following dopamine elevation with gamma-hydroxybutyrate (GHB, -16%) or levodopa (-20%). We suggest that in vivo (+)-[11C]DTBZ binding in imaging studies is subject to competition by vesicular dopamine and, in this respect, is not a "stable" dopamine biomarker as is generally assumed. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720517     DOI: 10.1002/syn.20573

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  17 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.

Authors:  Rajesh Narendran; Hank P Jedema; Brian J Lopresti; Neale Scott Mason; Michael L Himes; Charles W Bradberry
Journal:  Biol Psychiatry       Date:  2014-06-23       Impact factor: 13.382

Review 3.  Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Authors:  Stephen J Kish; Isabelle Boileau; Russell C Callaghan; Junchao Tong
Journal:  Eur J Neurosci       Date:  2016-09-05       Impact factor: 3.386

4.  Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment.

Authors:  Leigh Christopher; Connie Marras; Sarah Duff-Canning; Yuko Koshimori; Robert Chen; Isabelle Boileau; Barbara Segura; Oury Monchi; Anthony E Lang; Pablo Rusjan; Sylvain Houle; Antonio P Strafella
Journal:  Brain       Date:  2013-12-12       Impact factor: 13.501

5.  In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers.

Authors:  Rajesh Narendran; Brian J Lopresti; Diana Martinez; Neale Scott Mason; Michael Himes; Maureen A May; Dennis C Daley; Julie C Price; Chester A Mathis; W Gordon Frankle
Journal:  Am J Psychiatry       Date:  2011-10-31       Impact factor: 18.112

6.  Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.

Authors:  Vesna Sossi; Katherine Dinelle; Michael Schulzer; Edwin Mak; Doris J Doudet; Raúl de la Fuente-Fernández
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-10       Impact factor: 9.236

7.  Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates.

Authors:  Anne M Landau; M Mallar Chakravarty; Campbell M Clark; Athanasios P Zis; Doris J Doudet
Journal:  Neuropsychopharmacology       Date:  2010-10-13       Impact factor: 7.853

Review 8.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

9.  Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.

Authors:  Isabelle Boileau; Tina McCluskey; Junchao Tong; Yoshiaki Furukawa; Sylvain Houle; Stephen J Kish
Journal:  Neuropsychopharmacology       Date:  2015-08-31       Impact factor: 7.853

10.  VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination.

Authors:  P K Multani; R Hodge; M A Estévez; T Abel; H Kung; M Alter; B Brookshire; I Lucki; A H Nall; K Talbot; G A Doyle; F W Lohoff
Journal:  Neuroscience       Date:  2012-11-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.